Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
26/08/2026 12:17
BUZZ-Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million ** Shares of drugmaker Biohaven BHVN.N rise 14% to $16.4 premarket
** Biohaven enters a partnership with South Korean drug maker SK Biopharmaceuticals 326030.KS worth up to $795 million to license and commercialize a new epilepsy drug platform
** SK Biopharmaceuticals gains exclusive global rights to Biohaven's lead epilepsy drug candidate, opakalim
** Opakalim is in mid-to-late stage trial testing for focal epilepsy, and trial results are expected in H2 2026
** Biohaven to use SK's established epilepsy development and sales network to bring opakalim to patients globally
** As of last close, BHVN up 27.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean